Checkpoint Therapeutics 미래 성장

Future 기준 확인 5/6

Checkpoint Therapeutics은 연간 수입과 매출이 각각 46.1%와 42.7% 증가할 것으로 예상되고 EPS는 연간 48.5%만큼 증가할 것으로 예상됩니다.

주요 정보

46.1%

수익 성장률

48.5%

EPS 성장률

Biotechs 수익 성장	27.2%
매출 성장률	42.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	13 Jan 2025

최근 미래 성장 업데이트

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11

수익 및 매출 성장 예측

NasdaqCM:CKPT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	915	560	560	560	1
12/31/2026	186	85	85	85	1
12/31/2025	52	-7	29	26	3
12/31/2024	0	-36	-37	-33	4
9/30/2024	0	-46	-31	-31	N/A
6/30/2024	0	-42	-34	-34	N/A
3/31/2024	0	-52	-40	-40	N/A
12/31/2023	0	-52	-48	-48	N/A
9/30/2023	0	-54	-56	-56	N/A
6/30/2023	0	-59	-53	-53	N/A
3/31/2023	0	-56	-52	-52	N/A
12/31/2022	0	-63	-58	-58	N/A
9/30/2022	0	-71	-52	-52	N/A
6/30/2022	0	-72	-47	-47	N/A
3/31/2022	0	-67	-41	-41	N/A
12/31/2021	0	-57	-26	-26	N/A
9/30/2021	0	-37	-22	-22	N/A
6/30/2021	0	-31	-20	-20	N/A
3/31/2021	0	-26	-17	-17	N/A
12/31/2020	1	-23	-17	-17	N/A
9/30/2020	1	-22	-16	-16	N/A
6/30/2020	1	-22	-15	-15	N/A
3/31/2020	2	-22	-18	-18	N/A
12/31/2019	2	-25	-21	-21	N/A
9/30/2019	5	-28	-24	-24	N/A
6/30/2019	4	-32	-27	-27	N/A
3/31/2019	4	-33	-29	-29	N/A
12/31/2018	4	-36	-26	-26	N/A
9/30/2018	1	-31	-22	-22	N/A
6/30/2018	1	-27	N/A	-20	N/A
3/31/2018	1	-27	N/A	-18	N/A
12/31/2017	2	-23	N/A	-15	N/A
9/30/2017	2	-25	N/A	-15	N/A
6/30/2017	2	-24	N/A	-14	N/A
3/31/2017	3	-23	N/A	-11	N/A
12/31/2016	3	-22	N/A	-10	N/A
9/30/2016	2	-22	N/A	-7	N/A
6/30/2016	2	-21	N/A	-7	N/A
3/31/2016	0	-16	N/A	-5	N/A
12/31/2015	1	-14	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CKPT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: CKPT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: CKPT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: CKPT 의 수익(연간 42.7% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: CKPT 의 수익(연간 42.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CKPT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/21 20:34
장 마감 주가	2025/01/17 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Checkpoint Therapeutics, Inc. 8 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Justin Walsh	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
Jonathan Aschoff	B. Riley Wealth

Checkpoint Therapeutics 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 7.4% to US$15.75

Consensus revenue estimates fall by 30%

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$21.67

No longer forecast to breakeven

Consensus revenue estimates increase by 25%, EPS downgraded

Recent updates

Price target decreased by 7.4% to US$15.75

New minor risk - Share price stability

President recently sold US$3.1m worth of stock

Checkpoint Therapeutics, Inc. Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)

Consensus revenue estimates fall by 30%

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Consensus revenue estimates increase by 11%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Checkpoint Therapeutics, Inc Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Price target increased by 19% to US$21.67

Checkpoint Therapeutics, Inc. announced a financing transaction

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.000001 million.

President recently sold US$50k worth of stock

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

No longer forecast to breakeven

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024

Insufficient new directors

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

New major risk - Financial position

New major risk - Share price stability

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000001 million.

Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024

Consensus revenue estimates increase by 25%, EPS downgraded

U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer

Consensus revenue estimates increase by 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

First quarter 2023 earnings released: US$0.89 loss per share (vs US$1.98 loss in 1Q 2022)

Consensus revenue estimates increase by 41%

Price target decreased by 42% to US$33.50

Consensus revenue estimates decrease by 78%, EPS upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$103

Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Forecast to breakeven in 2024

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 3Q 2021)

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Price target decreased to US$17.60

Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CFO, Corporate Secretary & Treasurer recently sold US$72k worth of stock

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

CFO, Corporate Secretary & Treasurer recently sold US$93k worth of stock

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Forecast to breakeven in 2024

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma